Xpert MTB/RIF Ultra can better diagnose TB in children and people living with HIV
Sunnyvale, CA, USA; New Brunswick, NJ, USA; Geneva, Switzerland – 24 March 2017 -- On World TB Day, Cepheid, Rutgers New Jersey Medical School and FIND today announced a new version of the Xpert MTB/RIF test, the Xpert® MTB/RIF Ultra (Ultra), for the diagnosis of TB and rifampicin resistance. The World Health Organization (WHO) earlier today issued a recommendation that Ultra can be used as an alternative to the existing Xpert MTB/RIF test for the diagnosis of TB and detection of rifampicin resistance in all settings1.
Providing Rapid Molecular Diagnostic Results
in as little as 20 minutes
SUNNYVALE, Calif., Feb. 15, 2017 /PRNewswire/ -- Cepheid today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market Xpert® Xpress Flu and Xpert Xpress Flu/RSV. Both tests deliver reference-quality molecular results in as little as twenty minutes. The tests are Cepheid's first Xpress branded products — all of which are expected to deliver results in 30 minutes or less.1
SUNNYVALE, Calif., Dec. 19, 2016 /PRNewswire/ -- Cepheid today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for Xpert® MRSA NxG, the next generation methicillin-resistant Staphylococcus aureus (MRSA) infection control test from the leader in healthcare-associated infection (HAI) testing. Xpert® MRSA NxG is an accurate, on-demand, molecular test that delivers actionable results in about an hour.
WASHINGTON, Nov. 4, 2016 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher") announced that today it completed its acquisition of Cepheid (NASDAQ: CPHD).
Copper Merger Sub, Inc. ("Copper"), a California corporation and an indirect wholly owned subsidiary of Danaher, has merged into Cepheid and, as a result, Cepheid has become an indirect wholly owned subsidiary of Danaher. In the merger, each outstanding share of Cepheid common stock was cancelled and (except for shares held by Danaher, Copper, Cepheid and their respective subsidiaries) converted into the right to receive $53.00 per share in cash, without interest.